Qureight is a techbio company using AI to curate and analyse the complex medical images and data behind clinical trials, with a particular focus on deep lung diseases such as pulmonary fibrosis. Its Core Imaging Platform and Synthetic Study Arm help biopharma companies run leaner, faster trials, and it works with major drug developers to bring new treatments to patients sooner. Founded in Cambridge and led by clinician and co-founder Dr Muhunthan Thillai, it pairs world-class clinicians with software engineers and AI scientists.

By the time Qureight came to SomX it had the science, the partnerships and real commercial traction, but its public profile lagged well behind. It needed communications that could keep pace with a dense run of announcements, translate complex science into a story that resonated beyond specialists, and raise its profile with pharma, biotech and investors ahead of a planned fundraise. Much of the technical detail had become hard to follow, and the wider significance of the work risked being lost. We built and ran a multi-channel programme to change that.

A strategic PR cadence

We mapped media activity to Qureight's milestones and kept momentum through a fast-moving announcement schedule. We led the communications behind its partnerships with Avalyn Pharma, RemedyCell, Rein and Vicore, placing the stories across Drug Discovery World, FirstWord Pharma, BioPharma APAC, Pharmaphorum, Drug Target Review, the Journal of Clinical Studies and Manufacturing Chemist. Between January and June 2025 the programme delivered more than twelve times the contracted volume of coverage without any drop in quality.

Translating complex science into a clear story

Qureight's technology is hard to explain, and its significance had become buried in jargon. We reshaped the narrative so that the Core Imaging Platform, Synthetic Study Arm and its AI imaging work read clearly to journalists and non-specialists without losing scientific accuracy. That meant sharpening terminology, drawing out the world-first elements of the work and making the case for why it matters in drug development, so the science could reach a much wider audience ahead of the raise.

Raising the founder and leadership profile

We built a consistent public presence for CEO and co-founder Dr Muhunthan Thillai and the wider leadership team, with Q&As in Drug Discovery World and Pharmafocus, a company profile in Startups Magazine, and thought leadership including a Health Tech World piece on building clinical confidence in AI. We also secured Qureight a place on the panel at Google's Future of Life Sciences Tech Forum, putting its leadership in front of an influential life sciences audience.

Design, deck and web refresh

Ahead of the fundraise we delivered a full visual redesign of Qureight's Q3 2025 investor deck and built a reusable template so the team could keep new decks on-brand. We also refreshed website and comms materials for consistency, including updates that let key sections of the site be managed easily in-house. The result was a brand and a set of investor materials that matched the ambition of the science.

Integrated delivery and stakeholder alignment

PR, content, design and strategy worked as one team so the message stayed consistent across earned and owned channels. As new internal leads and partners came on board, we aligned quickly on messaging and kept everyone moving through a high-velocity news cycle, with regular reporting and senior strategic input throughout.